Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: Results of an open-label, randomized, controlled phase II study (CERTO)

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1734-1740

  Vansteenkiste, Johan F ^a   Barlesi, F ^b   Waller, C F ^c   Bennouna, J ^d   Gridelli, C ^e   Goekkurt, E ^f   Verhoeven, D ^g   Szczesna, A ^h   Feurer, M ⁱ   Milanowski, J ^j   Germonpre, P ^k   Lena, H ^l   Atanackovic, D ^m   Krzakowski, M ⁿ   Hicking, C ^o   Straub, J ^o   Picard, M ^o   Schuette, W ^p   O'Byrne, K ^q  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e S G MOSCATI HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g Algemeen Ziekenhuis Klina   (Belgium)

^h Division III   (Poland)

ⁱ Lungenpraxis Munich   (Germany)

^j MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^k Pulmonary Medicine AZ Maria Middelares   (Belgium)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o MERCK KGAA   (Germany)

^p Hospital Martha Maria Halle Dölau   (Germany)

^q PRINCESS ALEXANDRA HOSPITAL   (Australia)

more..

Author keywords

Cilengitide; Integrins; NSCLC; PFS; Phase II; Randomized controlled trials

Indexed keywords

ALPHAVBETA5 INTEGRIN; CETUXIMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; TUMOR MARKER; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; EGFR PROTEIN, HUMAN; GEMCITABINE; NAVELBINE; SNAKE VENOM; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THROMBOEMBOLISM; VERY ELDERLY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VITRONECTIN; SNAKE VENOMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84941701943     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv219     Document Type: Article

References (15)

1. Reck M, Popat S, Reinmuth N et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014; 25(Suppl 3): iii27-iii39.
2. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
3. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
4. Caccavari F, Valdembri D, Sandri C et al. Integrin signaling and lung cancer. Cell Adh Migr 2010; 4: 124-129.
5. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-412.
6. Schittenhelm J, Klein A, Tatagiba MS et al. Comparing the expression of integrins αvβ3, αvβ5, αvβ6, αvβ8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. Int J Clin Exp Pathol 2013; 6: 2719-2732.
7. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-2718.
8. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs 2003; 4: 741-745.
9. Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25: 1651-1657.
10. Nabors LB, Mikkelsen T, Hegi ME et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118: 5601-5607.
11. Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-5617.
12. Pirker R, Pereira JR, von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-smallcell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2011; 13: 33-42.
13. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open 2012; 15: 329-340.
14. Manegold C, Vansteenkiste J, Cardenal F et al. A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Thorac Oncol 2009; 4(Suppl 1): S381-S382.
15. Stupp R, Hegi ME, Gorlia T et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-1108.